A detailed history of Voya Investment Management LLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 16,510 shares of TSVT stock, worth $49,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,510
Previous 16,634 0.75%
Holding current value
$49,364
Previous $64,000 20.31%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.85 - $5.05 $477 - $626
-124 Reduced 0.75%
16,510 $77,000
Q2 2024

Dec 03, 2024

BUY
$3.6 - $5.79 $446 - $717
124 Added 0.75%
16,634 $64,000
Q2 2024

Aug 14, 2024

BUY
$3.6 - $5.79 $2,095 - $3,369
582 Added 3.63%
16,634 $64,000
Q1 2024

Dec 06, 2024

SELL
$3.09 - $6.0 $1,415 - $2,748
-458 Reduced 2.77%
16,052 $85,000
Q1 2024

May 15, 2024

SELL
$3.09 - $6.0 $140,165 - $272,166
-45,361 Reduced 73.86%
16,052 $85,000
Q4 2023

Feb 14, 2024

BUY
$1.57 - $4.58 $17,959 - $52,390
11,439 Added 22.89%
61,413 $262,000
Q3 2023

Nov 14, 2023

BUY
$3.14 - $11.2 $48,236 - $172,054
15,362 Added 44.38%
49,974 $195,000
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $40,348 - $59,592
4,775 Added 16.0%
34,612 $350,000
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $126,990 - $251,906
14,818 Added 98.66%
29,837 $279,000
Q3 2022

Mar 03, 2023

SELL
$12.56 - $17.54 $186,114 - $259,907
-14,818 Reduced 49.66%
15,019 $218,000
Q3 2022

Nov 14, 2022

BUY
$12.56 - $17.54 $10,148 - $14,172
808 Added 5.69%
15,019 $219,000
Q2 2022

Aug 15, 2022

BUY
$10.55 - $18.81 $149,926 - $267,308
14,211 New
14,211 $188,000
Q1 2022

May 16, 2022

SELL
$11.67 - $26.72 $102,240 - $234,093
-8,761 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $120,638 - $372,868
8,761 New
8,761 $225,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $113M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.